Landing Page | Kyntra Bio
FibroGen (now operating as Kyntra Bio) is a biopharmaceutical company developing first-in-class medicines for life-threatening conditions, with a pipeline focused on anemia associated with lower-risk myelodysplastic syndrome and metastatic castration-resistant prostate cancer. Its lead programs include roxadustat, an oral HIF-PHI approved in multiple regions for anemia in chronic kidney disease, and FG-3246, an antibody-drug conjugate targeting prostate cancer.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2014
May 2013
Jan 2008
Jan 2005
Jan 2004
Aug 2002
Jan 2000
Create a free account to see which investors have funded this company.
Create Free Account
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
